Literature DB >> 26587453

Chinese Hypertension Guidelines.

Ji-Guang Wang1.   

Abstract

According to the 4th National Nutrition and Health Survey in 2002, the prevalence of hypertension in China was 18.8%. Although there are no recent updated nationwide data, it is believed that the prevalence of hypertension has increased substantially in the past decade up to more than 200 million hypertensive patients in the populous country of China. To fight against the growing risk of hypertension, three Chinese hypertension guidelines were compiled in the past two decades, in 1999, 2005, and 2011. The current guidance document for the management of hypertension was named '2010 Chinese hypertension guideline', but it was actually published in 2011. In this guideline, all five classes of antihypertensive drugs were recommended as possible initial and maintenance therapy. The goal of treatment was a systolic/diastolic blood pressure below 140/90 mm Hg in general, 130/80 mm Hg in various groups of high-risk patients, and 150/90 mm Hg in the elderly (≥65 years). With the recent publication of several national and international hypertension guidelines, the Chinese guideline is now under discussion for updating.

Entities:  

Keywords:  Antihypertensive drugs; Blood pressure control; Chinese hypertension guideline; Control rates; Prevalence; Treatment

Year:  2015        PMID: 26587453      PMCID: PMC4646151          DOI: 10.1159/000382025

Source DB:  PubMed          Journal:  Pulse (Basel)        ISSN: 2235-8668


  21 in total

1.  [National survey of blood pressure control rate in Chinese hypertensive outpatients-China STATUS].

Authors:  Da-yi Hu; Li-sheng Liu; Jin-ming Yu; Chong-hua Yao
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2010-03

2.  Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  J G Wang; J A Staessen; L Gong; L Liu
Journal:  Arch Intern Med       Date:  2000-01-24

3.  [A description on the Chinese national nutrition and health survey in 2002].

Authors:  Li-ming Li; Ke-qin Rao; Ling-zhi Kong; Chong-hua Yao; Hong-ding Xiang; Feng-ying Zhai; Guan-sheng Ma; Xiao-guang Yang
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2005-07

Review 4.  Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association.

Authors:  Ji-Guang Wang; Kazuomi Kario; Titus Lau; Yong Quek Wei; Chang Gyu Park; Cheol Ho Kim; Jun Huang; Weizhong Zhang; Yong Li; Peter Yan; Dayi Hu
Journal:  Hypertens Res       Date:  2011-01-13       Impact factor: 3.872

5.  Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study.

Authors:  Zhao-Jun Yang; Jie Liu; Jia-Pu Ge; Li Chen; Zhi-Gang Zhao; Wen-Ying Yang
Journal:  Eur Heart J       Date:  2011-06-30       Impact factor: 29.983

6.  [2010 Chinese guidelines for the management of hypertension].

Authors:  Li-Sheng Liu
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2011-07

7.  The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.

Authors:  Lisheng Liu; Yuqing Zhang; Guozhang Liu; Wei Li; Xuezhong Zhang; Alberto Zanchetti
Journal:  J Hypertens       Date:  2005-12       Impact factor: 4.844

8.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

10.  Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.

Authors:  Qi-Fang Huang; Chang-Sheng Sheng; Yan Li; Gen-Shan Ma; Qiu-Yan Dai; Ji-Guang Wang
Journal:  Drugs R D       Date:  2013-06
View more
  21 in total

1.  Hypertension Guidelines: Timely New Initiatives from East Asia.

Authors:  John Chalmers
Journal:  Pulse (Basel)       Date:  2015-04-29

2.  Health-related quality of life among rural men and women with hypertension: assessment by the EQ-5D-5L in Jiangsu, China.

Authors:  Zhuoru Liang; Tiantian Zhang; Tengfei Lin; Lishun Liu; Binyan Wang; Alex Z Fu; Xiaobin Wang; Xiping Xu; Nan Luo; Jie Jiang
Journal:  Qual Life Res       Date:  2019-03-04       Impact factor: 4.147

3.  Relationship of serum immunoglobulin levels to blood pressure and hypertension in an adult population.

Authors:  Xiaotong Wang; Yajun Li; Huihui Li; Yeqing Gu; Yanqi Song; Qing Zhang; Li Liu; Ge Meng; Zhanxin Yao; Hongmei Wu; Yang Xia; Xue Bao; Hongbin Shi; Qian Su; Liyun Fang; Huijun Yang; Fei Yu; Shaomei Sun; Xing Wang; Ming Zhou; Huanli Jiao; Qiyu Jia; Kun Song; Yuntang Wu; Hong Chang; Kaijun Niu
Journal:  J Hum Hypertens       Date:  2018-02-07       Impact factor: 3.012

4.  Guidelines for the design and conduct of human clinical trials on ingestion-time differences - chronopharmacology and chronotherapy - of hypertension medications.

Authors:  Ramón C Hermida; Michael H Smolensky; Horia Balan; Richard J Castriotta; Juan J Crespo; Yaron Dagan; Sherine El-Toukhy; José R Fernández; Garret A FitzGerald; Akio Fujimura; Yong-Jian Geng; Ramón G Hermida-Ayala; Antonio P Machado; Luiz Menna-Barreto; Artemio Mojón; Alfonso Otero; R Daniel Rudic; Eva Schernhammer; Carsten Skarke; Tomoko Y Steen; Martin E Young; Xiaoyun Zhao
Journal:  Chronobiol Int       Date:  2020-12-20       Impact factor: 3.749

5.  Prevalence, awareness, and associated factors of high blood pressure among female migrant workers in Central South China.

Authors:  Hua Peng; Mei Sun; Xin Hu; Huiwu Han; Jing Su; Emin Peng; James Wiley; Lisa Lommel; Jyu-Lin Chen
Journal:  PeerJ       Date:  2022-05-04       Impact factor: 3.061

6.  Association of peripheral differential leukocyte counts with dyslipidemia risk in Chinese patients with hypertension: insight from the China Stroke Primary Prevention Trial.

Authors:  Yanhong Liu; Xiangyi Kong; Wen Wang; Fangfang Fan; Yan Zhang; Min Zhao; Yi Wang; Yupeng Wang; Yu Wang; Xianhui Qin; Genfu Tang; Binyan Wang; Xiping Xu; Fan Fan Hou; Wei Gao; Ningling Sun; Jianping Li; Scott A Venners; Shanqun Jiang; Yong Huo
Journal:  J Lipid Res       Date:  2016-11-22       Impact factor: 5.922

7.  Guidance on home blood pressure monitoring: A statement of the HOPE Asia Network.

Authors:  Kazuomi Kario; Sungha Park; Peera Buranakitjaroen; Yook-Chin Chia; Chen-Huan Chen; Romeo Divinagracia; Satoshi Hoshide; Jinho Shin; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Jam Chin Tay; Yuda Turana; Lawrence Wong; Yuqing Zhang; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-16       Impact factor: 3.738

8.  Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults.

Authors:  Yuanli Dong; Xukui Liu; Yingxin Zhao; Qiang Chai; Hua Zhang; Yumei Gao; Zhendong Liu
Journal:  Front Cardiovasc Med       Date:  2021-06-17

9.  Changes in Adherence to Non-Pharmacological Guidelines for Hypertension.

Authors:  Kyong Park; Sukyung Cho; Julie K Bower
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

10.  Medication Adherence and Blood Pressure Control Among Hypertensive Patients With Coexisting Long-Term Conditions in Primary Care Settings: A Cross-Sectional Analysis.

Authors:  Yu Ting Li; Harry H X Wang; Kirin Q L Liu; Gabrielle K Y Lee; Wai Man Chan; Sian M Griffiths; Ruo Ling Chen
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.